New RSV drug tested in kids – but trial halted early
NCT ID NCT06102174
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the safety and dosing of sisunatovir, an experimental antiviral drug, in infants and children up to 5 years old with RSV lower respiratory tract infection. Ten participants received either the drug or a placebo. The goal was to find the right dose for future studies. However, the trial was terminated early, so the full results may not be available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sisunatovir (also known as PF-07923568, RV521)
What this could lead to
If successful, this study could help determine the right dose of sisunatovir for future trials in children with RSV, potentially leading to a treatment for severe RSV infections.
What could go wrong
This is a very early (phase 1b) and small study (only 10 participants) focused on safety and dosing, not on proving the drug works. The trial was terminated, so results may be limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kaiser Permanente
Los Angeles, California, 90027, United States
-
Kaiser Permanente Los Angeles Medical center
Los Angeles, California, 90027, United States
-
Kojunkai Daido Hospital
Nagoya, Aichi-ken, 457-8511, Japan
-
Monti Clinical Research Centre
Mdantsane, Eastern Cape, 5219, South Africa
-
Nintenkai Kagoshima Children's Hospital
Hioki, Kagoshima-ken, 899-2503, Japan
-
Osaka City General Hospital
Osaka, 534-0021, Japan
-
University of Witwatersrand (WITS) - Vaccines and Infectious Diseases Analytics (VIDA)
Johannesburg, Gauteng, 2013, South Africa
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
-
Yamanashi Prefectural Central Hospital
Kofu, Yamanashi, 400-8506, Japan